{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54","upperLimit":"96","value":"86"},{"groupId":"OG001","lowerLimit":"20","upperLimit":"80","value":"56"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with Germ Cell Tumors (GCT) treated with a second tandem autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens.\n\ncarboplatin: Days -6, -5, -4: 500mg/m2\\^/day intravenously (IV) over 60 minutes\n\netoposide: 600mg/m\\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.\n\nthiotepa: 150mg/m\\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4\n\nautologous hematopoietic stem cell transplantation: Peripheral blood stem cell infusion (\\< 4 x 10\\^6 CD34+ cells/kg)\n\nfilgrastim: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.","id":"OG000","title":"2 Transplants"},{"description":"Patients with Germ cell tumors who receive one transplant only.\n\nifosfamide: 2500 mg/m\\^2/day continuous infusion intravenously on Days -6, -5 and -4.\n\npaclitaxel: 225 mg/m\\^2 intravenous over 3 hours on Day -7.\n\nautologous hematopoietic stem cell transplantation: Peripheral blood stem cell infusion (\\< 4 x 10\\^6 CD34+ cells/kg)\n\nMesna: 2500 mg/m\\^2/day continuous infusion intravenously on Days -6, -5 and -4.\n\nfilgrastim: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.","id":"OG001","title":"1 Transplant"}],"paramType":"MEAN","populationDescription":"The protocol is essentially one single-arm, but patients received either one or two transplants depending on the cells they had available and we are reporting results for these two groups.","reportingStatus":"POSTED","timeFrame":"1 Year","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}